source
- Pharma access plans rise to 69% of late-stage drugs but gaps remain for non-communicable diseasesA new analysis shows that many large drug makers are expanding programs to make medicines available in low- and middle‑income markets, but progress is uneven across disease areas. Access plans now…
- AstraZeneca acquires Omniose to boost bacterial vaccine capabilitiesAstraZeneca has completed the purchase of Omniose, a specialist in vaccine bioconjugation, making the company a wholly owned subsidiary of its infectious disease division. The two firms began coll…